keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/28058154/intravitreal-dexamethasone-implant-ozurdex-for-refractory-macular-edema-secondary-to-retinitis-pigmentosa
#1
Nurgül Örnek, Kemal Örnek, İnci Elif Erbahçeci
Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved...
August 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#2
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#3
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/28012104/intravitreal-dexamethasone-implant-for-the-treatment-of-cystoid-macular-oedema-associated-with-acute-retinal-necrosis
#4
Parthopratim Dutta Majumder, Jyotirmay Biswas, Asra Ambreen, Rowayda Amin, Zahedur Rahman Pannu, Ahmed Magdy Bedda
BACKGROUND: Acute retinal necrosis is a rare but devastating ocular condition. We report two cases of acute retinal necrosis in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal dexamethasone (OZURDEX®) implant. RESULTS: Two patients diagnosed with acute retinal necrosis were treated with intravenous acyclovir. Both of them developed cystoid macular oedema following resolution of viral retinitis. Ocular condition of the first patient was further complicated by central serous chorioretinopathy...
December 2016: Journal of Ophthalmic Inflammation and Infection
https://www.readbyqxmd.com/read/27999699/location-of-a-dexamethasone-implant-at-the-macula-after-intravitreal-injection-in-a-silicone-oil-filled-eye
#5
Cenap Mahmut Esenulku, Murat Gunay
Here, we report a case with cystoid macular edema (CME) due to central retinal vein occlusion (CRVO) presented with a dexamethasone implant (Ozurdex) trapped at the macula in her silicone oil- (SO-) filled eye after injection. No additional complications such as intraocular pressure (IOP) rise or retinal damage were observed. The CME was resolved during the follow-up period. At the last visit, 3 months following the injection, Ozurdex implant was found to be mostly dissolved without any additional ocular complications...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27957602/erratum-to-dexamethasone-intravitreal-implant-in-retinal-vein-occlusion-real-life-data-from-a-prospective-multicenter-clinical-trial
#6
Nicole Eter, Andreas Mohr, Joachim Wachtlin, Nicolas Feltgen, Andrew Shirlaw, Richard Leaback
No abstract text is available yet for this article.
January 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/27926906/long-term-real-life-efficacy-and-safety-of-repeated-ozurdex%C3%A2-injections-and-factors-associated-with-macular-edema-resolution-after-retinal-vein-occlusion-the-remido-2-study
#7
Stéphan Pommier, Franck Meyer, Sébastien Guigou, Tony Barthelemy, Fréderic Gobert, Christian Hajjar, Pierre-Yves Merite, Eric Parrat, Hervé Rouhette, Fréderic Matonti
PURPOSE: The objective was to study long-term real-life efficacy and safety of repeated Ozurdex® injections and factors associated with macular edema (ME) resolution after retinal vein occlusion. METHODS: Patients with ME after retinal vein occlusion, receiving Ozurdex®, were included to assess the following endpoints: visual acuity and central retinal thickness, retreatment, number of injections, side effects and ME resolution. ME resolution was defined as permanent discontinuation of intravitreal injections (IVTs) for at least 6 months after the last IVT...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27915343/intravitreal-dexamethasone-implant-for-the-treatment-of-postoperative-macular-edema
#8
André Klamann, Katharina Böttcher, Philipp Ackermann, Gerd Geerling, Marc Schargus, Rainer Guthoff
INTRODUCTION: Macular edema after cataract surgery (Irvine-Gass syndrome) or pars plana vitrectomy is a postoperative complication which can lead to permanent visual loss. Increased inflammatory substances, such as prostaglandins and cytokines, are discussed to be causative. Currently, there are no evidence-based guidelines for the treatment of postoperative macular edema. Intravitreal dexamethasone (DEX) could be effective by its anti-inflammatory effect. We examined the functional and morphological results of treatment with 0...
2016: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/27893624/prospective-evaluation-of-a-sustained-release-dexamethasone-intravitreal-implant-for-cystoid-macular-edema-in-quiescent-uveitis
#9
Rahul N Khurana, Alok S Bansal, Louis K Chang, James D Palmer, Chengqing Wu, Mark R Wieland
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred...
November 23, 2016: Retina
https://www.readbyqxmd.com/read/27882244/evaluation-of-peripapillary-nerve-fiber-layer-after-dexamethasone-implantation-ozurdex-in-branch-retinal-vein-occlusions
#10
Muhammed Nurullah Bulut, Yusuf Özertürk, Ümit Çallı, Güzide Akçay, Ulviye Kıvrak, Kezban Bulut
Purpose. To evaluate the peripapillary retinal nerve fiber layer (RNFL) thicknesses of patients treated with intravitreal Ozurdex implant due to branch retinal vein occlusion (BRVO) related macular edema (ME). Methods. Thirty-three eyes of 33 patients treated with Ozurdex implant due to ME associated with BRVO were included in the study. Ophthalmic examinations including determination of best corrected visual acuity (BCVA), measurement of intraocular pressure (IOP), and central macular thickness (CMT) and peripapillary RNFL assessment with optical coherence tomography (OCT) were performed before the injection of Ozurdex implant and during the 6-month follow-up period after the injection...
2016: Journal of Ophthalmology
https://www.readbyqxmd.com/read/27806001/ocular-hypertension-after-intravitreal-dexamethasone-ozurdex-sustained-release-implant
#11
Eric K Chin, David R P Almeida, Gabriel Velez, Kunyong Xu, Maria Peraire, Maria Corbella, Yasser M Elshatory, Young H Kwon, Karen M Gehrs, H Culver Boldt, Elliott H Sohn, Stephen R Russell, James C Folk, Vinit B Mahajan
PURPOSE: To evaluate ocular hypertension (OHT) after Ozurdex injection to determine the incidence of OHT, therapy for OHT, and any associative factors such as diagnosis, underlying glaucoma and therapy, or sequential Ozurdex injection(s). METHODS: Retrospective consecutive case series with patients receiving one or more intravitreal Ozurdex implantations at a tertiary care academic center. Ocular hypertension was defined as a single measurement of ≥30 mmHg or an increase of ≥10 mmHg from baseline...
November 1, 2016: Retina
https://www.readbyqxmd.com/read/27803859/an-eighteen-month-follow-up-study-on-the-effects-of-intravitreal-dexamethasone-implant-in-diabetic-macular-edema-refractory-to-anti-vegf-therapy
#12
Fernanda Pacella, Maria Rosaria Romano, Paolo Turchetti, Giovanna Tarquini, Anna Carnovale, Antonella Mollicone, Alessandra Mastromatteo, Elena Pacella
AIM: To evaluate the long-term efficacy and safety of dexamethasone implants in subjects affected by diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Thirty-two DME patients were enrolled. A 700 microgram slow release Intravitreal Dexamethasone Implant (Ozurdex(®)) was placed in the vitreous cavity. All patients were followed for 18mo. Best-corrected visual acuity (BCVA) measured with Early Treatment Diabetic Retinopathy Study (ETDRS) and central macular thickness (CMT) exams were carried out at baseline (T0) and after 1 (T1), 3 (T3), 4 (T4), 6 (T6), 9 (T9), 12 (T12), 15 (T15), and 18mo (T18) post injection...
2016: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/27800199/-magic-bullet-eccentric-macular-hole-as-a-complication-from-dexamethasone-implant-insertion
#13
Logan Christensen, Riley Sanders, Jeffrey Olson
Introduction. Intravitreal drug injections and implants are generally safe but do carry some risk, from both the procedure itself and adverse effects of the medications. We report a case of an eccentric macular hole after dexamethasone implant (Ozurdex®) administration. Ex vitro force testing was performed to evaluate dexamethasone implant injection force. Methods. Five dexamethasone implant (Ozurdex) applicators were placed 16 mm from a force plate and the force of the injected dexamethasone pellet was recorded in Newtons...
2016: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/27778454/quantification-of-fluid-resorption-from-diabetic-macular-oedema-with-foveal-serous-detachment-after-dexamethasone-intravitreal-implant-ozurdex-%C3%A2-in-a-pregnant-diabetic
#14
Delila Hodzic-Hadzibegovic, Shakoor Ba-Ali, Marianne Valerius, Henrik Lund-Andersen
PURPOSE: To quantify the fluid resorption from the centre of the fovea in a pregnant woman with diabetic macular oedema by daily optical coherence tomography (OCT) measurements after the administration of intravitreal dexamethasone implant (Ozurdex(®) ). METHODS: A 36-year-old pregnant woman with type 1 diabetes for 33 years presented with diabetic macular oedema with foveal serous detachment and symptomatic vision loss at 16 gestational weeks. Best-corrected visual acuity (BCVA) in Snellen notation and central retinal volume assessed by optical coherence tomography (OCT, Topcon Corporation) were measured almost on a daily basis the first five weeks after implantation and then 2-3 times per month until childbirth...
October 24, 2016: Acta Ophthalmologica
https://www.readbyqxmd.com/read/27768792/vision-related-quality-of-life-outcomes-in-the-bevordex-study-a-clinical-trial-comparing-ozurdex-sustained-release-dexamethasone-intravitreal-implant-and-bevacizumab-treatment-for-diabetic-macular-edema
#15
Christine Aroney, Samantha Fraser-Bell, Ecosse L Lamoureux, Mark C Gillies, Lyndell L Lim, Eva K Fenwick
Purpose: To determine the patient-centered effectiveness of treatment with the slow-release dexamethasone intravitreal implant (DEX implant) and intravitreal bevacizumab using the Impact of Vision Impairment Questionnaire (IVI), a vision-related quality of life (VRQoL) measure, in patients with visual impairment secondary to center-involving diabetic macular edema (DME). Methods: Patients with DME were enrolled in a phase 2, prospective, multicenter, randomized, single-masked clinical trial and received either DEX implant 4 monthly or bevacizumab monthly, both pro re nata...
October 1, 2016: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/27768641/safety-of-intravitreal-dexamethasone-implant-ozurdex-the-safodex-study-incidence-and-risk-factors-of-ocular-hypertension
#16
Ariane Malclès, Corinne Dot, Nicolas Voirin, Anne-Laure Vié, Émilie Agard, David Bellocq, Philippe Denis, Laurent Kodjikian
PURPOSE: To analyze the incidence, risk factors, and time course of intraocular pressure elevation after intravitreal dexamethasone implant (Ozurdex). METHODS: The medical charts of 421 consecutive eyes (361 patients) receiving one or more Ozurdex implant between October 2010 and February 2015 were reviewed retrospectively. Ocular hypertension was defined as intraocular pressure of at least 25 mmHg or an increase of at least 10 mmHg from baseline. The main indications for treatment were retinal vein occlusion (34%), diabetic macular edema (30%), postsurgical macular edema (17%), uveitis (14%), and other etiologies (5%)...
October 20, 2016: Retina
https://www.readbyqxmd.com/read/27733187/management-of-anterior-chamber-dislocation-of-a-dexamethasone-intravitreal-implant-a-case-report
#17
Fernanda Pacella, Enzo Agostinelli, Sandra Cinzia Carlesimo, Marcella Nebbioso, Roberto Secondi, Michele Forastiere, Elena Pacella
BACKGROUND: Ozurdex is a 700 mcg dexamethasone intravitreal implant, approved for the management of macular edema secondary to retinal vein occlusion, and other related pathoglogiesAnterior chamber dislocation of Ozurdex represents an uncommon complication of the intravitreal injection, which can be managed by repositioning the implant into the vitreous cavity. We describe the case of a successful repositioning of an Ozurdex implant by mobilization and subsequent balanced saline solution injection in the anterior chamber...
October 13, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27626149/short-term-effects-of-intravitreal-dexamethasone-implant-ozurdex%C3%A2-on-choroidal-thickness-in-patients-with-naive-branch-retinal-vein-occlusion
#18
Hasan Basri Arifoglu, Necati Duru, Orhan Altunel, Burhan Baskan, Bedirhan Alabay, Mustafa Atas
PURPOSE: The objective of this study was to evaluate subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography (EDI-OCT) in patients with naïve branch retinal vein occlusion (BRVO) before and after intravitreal dexamethasone implant (Ozurdex®) injection. METHODS: Thirty-nine patients with unilateral BRVO and 35 healthy subjects were included in this prospective study. Choroidal thickness was evaluated by EDI-OCT at baseline and 1 month after dexamethasone implant...
July 2016: Arquivos Brasileiros de Oftalmologia
https://www.readbyqxmd.com/read/27612922/comparison-of-dexamethasone-intravitreal-implant-with-conventional-triamcinolone-in-patients-with-postoperative-cystoid-macular-edema
#19
Georgios Mylonas, Michael Georgopoulos, Panagiotis Malamos, Ilias Georgalas, Chryssanthi Koutsandrea, Dimitrios Brouzas, Stefan Sacu, Christos Perisanidis, Ursula Schmidt-Erfurth
AIMS: To evaluate the efficacy of the treatment with intravitreal triamcinolone acetonide or dexamethasone intravitreal implant in patients with postoperative cystoid macular edema (PCME). MATERIALS AND METHODS: Thirty eyes of 29 patients with PCME were randomized into two groups: one group initially received an injection of 4 mg triamcinolone; retreatment after 3 months was dependent on functional and anatomic outcome in a PRN regimen. The second group received a single injection of the dexamethasone intravitreal implant (Ozurdex)...
September 9, 2016: Current Eye Research
https://www.readbyqxmd.com/read/27599562/the-effect-of-age-on-dexamethasone-intravitreal-implant-ozurdex%C3%A2-response-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#20
Orhan Altunel, Altan Göktaş, Necati Duru, Ayşe Özköse, Hasan Basri Arifoğlu, Mustafa Ataş
PURPOSE: To investigate the effect of age on dexamethasone intravitreal implant (Ozurdex®) response in macular edema secondary to branch retinal vein occlusion (BRVO). METHODS: Seventy-three eyes of 73 patients with macular edema secondary to BRVO were recruited in the study. The patients in the study were divided into the following four groups according to their ages: group 1 (<60 years), group 2 (60-69 years), group 3 (70-79 years), and group 4 (≥80 years)...
September 6, 2016: Seminars in Ophthalmology
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"